Overview

Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders

Status:
COMPLETED

Trial end date:
2025-07-22

Target enrollment:

Participant gender:

Summary

This study is designed to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses and ratios of xanomeline and trospium chloride in an IR capsule (KarXT) and dual-burst release of xanomeline with immediate-release trospium chloride in adolescents with psychiatric disorders.

Phase:

PHASE1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

trospium chloride
xanomeline